A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.
By inhibiting a certain protein, the researchers were able to reduce the signals that trigger an inflammation. The study is published in Science and was done in collaboration with the University of Texas Medical Branch, Uppsala University and Stockholm University.
“We’ve developed a new drug molecule that inhibits inflammation,” says Professor Thomas Helleday, at the Department of Oncology-Pathology, Karolinska Institutet, Sweden, who co-led the study with Dr Torkild Visnes and Dr Armando Cázares-Körner. “It acts on a protein that we believe is a general mechanism for how inflammation arises in cells.”
The discovery is the result of many years of research by Thomas Helleday’s group on how DNA is repaired by the body. One of the objectives has been to fight cancer by targeting damage to the tumour cells’ DNA. Several breakthroughs have already been reported, which have led, amongst other things, to a new treatment for congenital breast and ovarian cancer using so-called PARP inhibitors, which has been available for some years.
Trials on mice
It was when developing a new molecule for inhibiting the enzyme that repairs oxygen damage to DNA that the researchers found, to their surprise, that it also dampened inflammation. It turned out that the enzyme OGG1, apart from repairing DNA, also triggers inflammation.
The inhibitor blocks the release of inflammatory proteins, such as TNF alpha. In trials on mice with acute pulmonary disease, the researchers succeeded in dampening the inflammation.
“This discovery could give rise to a new treatment for a very serious condition,” says Professor Helleday. “We’ll now be developing our OGG1 inhibitor and examining whether it can lead to new treatments for inflammatory diseases in order to cure or relieve diseases such as sepsis, COPD and severe asthma.”
The discovery was made in collaboration with Professor Istvan Boldogh from the University of Texas Medical Branch, USA.
The repair pathway on which OGG1 operates was discovered by Tomas Lindahl at Karolinska Institutet in the 1970s, an achievement that earned him the Nobel Prize in Chemistry in 2015.
Collaboration between several universities
The study was a collaboration between Karolinska Institutet, Uppsala University and Stockholm University in Sweden and the University of Texas Medical Branch, USA.
Learn more: New inflammation inhibitor discovered
The Latest on: Anti-inflammatory drug
via Google News
The Latest on: Anti-inflammatory drug
- Trump Still On Steroids: How These Drugs Are Typically Used To Treat COVID-19on October 8, 2020 at 1:16 pm
President Trump says he's still taking the drug dexamethasone to treat COVID-19. It's a cheap, widely available steroid. But how long should COVID patients take it and what are the side effects?
- Prescription Pet Medications Now Available in Georgia Publix Pharmacieson October 8, 2020 at 8:03 am
anti-inflammatory and antifungal) endocrine (Addison’s disease, Cushing’s syndrome, diabetes and hypothyroidism) heart failure heartworm, flea and tick motion sickness and seizures. Publix Pharmacy ...
- Rheumatoid Arthritis Drugs Market to Generate $62.93 Bn, by 2027, at 2.8% CAGR: AMRon October 8, 2020 at 6:45 am
Allied Market Research published a report, titled, "Rheumatoid Arthritis Drugs Market by Therapeutic Molecule (Pharmaceuticals ...
- Worldwide Industry for Pain Management Drugs to 2027 - Advancements in Drug Development Presents Opportunitieson October 8, 2020 at 2:42 am
The "Pain Management Drugs Market by Drug Class and Indication: Global Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering. The global ...
- Drug May Reduce COVID-19 Mortality Rates for Diabetic Patients, Study by HMS Professor Findson October 7, 2020 at 9:40 pm
The drug sitagliptin may reduce mortality rates for diabetic patients hospitalized with COVID-19, an observational study led by Paulo Fiorina, assistant professor of pediatrics at Harvard Medical ...
- Trump's coronavirus drugs: Regeneron, dexamethasone and more, explainedon October 7, 2020 at 4:05 pm
The president has received an interesting mix of experimental treatments often used in more severe cases of COVID-19.
- Anti-Inflammatory Biologics Market 2020: Global Size, Growth Factors, Emerging Technologies, Major Segments, Forecast Research Report 2026on October 5, 2020 at 11:47 pm
Inflammatory Biologics Market Size” is expected to reach USD 149.80 billion by 2027, exhibiting a CAGR of 11.0% during the forecast period. The indication of an inflammatory surplus in patients with ...
- Development of Next-Generation Drugs to Inhibit Ravages of Chronic Inflammationon October 5, 2020 at 5:41 am
Multiple studies indicate that chronic inflammation triggers a cascade of disease-causing effects. The condition has also been linked to Alzheimer's disease, cancer, heart disease and diabetes among ...
- Dexamethasone: Rare Side Effect of Drug Given to Trump for COVID Includes Grandiose Delusionson October 5, 2020 at 2:33 am
President Donald Trump has been prescribed dexamethasone for COVID-19, a steroid that has a range of potential side effects including mental problems such as aggression, agitation, and anxiety. At a ...
via Bing News